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Abstract: Coronary stent thrombosis is a serious problem in the drug-eluting stent era. Despite 
aggressive antiplatelet therapy during and after percutaneous coronary intervention (PCI), the 
incidence of sub-acute stent thrombosis remains approximately 0.5%–2%, which may represent a 
catastrophic clinical situation. Both procedural factors and discontinuation of antiplatelet therapy 
are normally associated with this event. We report on simultaneous stent thromboses of two 
drug-eluting stents implanted in two different vessels, which resulted in a life-threatening clinical 
condition. Possible contributing factors that led to synergistic thrombotic effects are discussed.
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Simultaneous thromboses of two coronary artery 
stents: fostering bad synergies
The patient is a 47-year-old woman from Morocco with a history of insulin-requiring 
type 2 diabetes mellitus (DM), dyslipidemia, and obesity (body mass index: 33), 
admitted to our institution during the acute phase of ST elevation myocardial infarc-
tion (STEMI). One week before the current admission, the patient had been admitted 
to another center with progressive angina pectoris (functional class III). Coronary 
angiography revealed severe coronary stenoses in the proximal segment of the right 
coronary artery (RCA) and in the distal segment of the left anterior descending (LAD) 
artery. At that time, PCI of both lesions was performed by implanting a 2.25 × 8 mm 
sirolimus-eluting stent (Cypher®, Cordis, Johnson and Johnson) in the distal LAD 
and a 2.5 × 13 mm stent in the proximal RCA. The patient was discharged on dual 
antiplatelet therapy (acetylsalycilic acid, ASA) 100 mg per day and clopidogrel 75 mg 
per day). Five days after the procedure, however, the patient decided to stop ASA 
although remained on clopidogrel. Two days later, the patient suffered from STEMI 
involving both anterior and inferior territories on the ECG. She also suffered repeated 
episodes of ventricular ﬁ  brillation, but was successfully deﬁ  brillated. The patient 
required inotropic support to maintain arterial pressure stability and was intubated 
because of repeated arrythmias. Emergency coronary angiography was performed 
and revealed thromboses of both stents (Figure 1). RCA thrombosis was tackled ﬁ  rst 
with abciximab bolus + infusion. The passage of the guidewire through the stent was 
very difﬁ  cult requiring the use of different wires. A hydrophilic wire was initially 
passed through the stent, but neither a thrombus aspiration catheter nor a 1.5 × 10 mm 
angioplasty balloon could cross through the stent successfully. Not until a second 
wire was sited in parallel (Figure 2A), while the balloon remained inserted over the 
ﬁ  rst wire at the point where it stopped, could we successfully dilate the stent with Vascular Health and Risk Management 2009:5 102
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Figure 1 Angiographic images of stent thrombosis on RCA (A) and LAD (B).
Figure 2 Panel A: successful passage of the wire, while the balloon is inserted over another wire at the place where it stopped. Panel B and C: Final angiographic result on 
RCA (B) and LAD (C).Vascular Health and Risk Management 2009:5 103
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noncompliant balloons (2.5 and 3.0 mm in diameter). Finally 
a new drug-eluting stent (DES) (Xience™, Abbott Vascular 
3.0 × 28 mm) was used to cover the entire segment includ-
ing the more proximal segment of the RCA up to the distal 
part of the previously implanted stent. A DES was chosen 
because the patient was diabetic. A good angiographic result 
(TIMI 3 ﬂ  ow) was obtained (Figure 2B). The LAD artery was 
treated sequentially. In this vessel, thrombus aspiration was 
effective and the result was optimized using a noncompliant 
balloon dilatation (2.5 × 9 mm) gaining a ﬁ  nal TIMI 3 ﬂ  ow 
(Figures 2B–C). The patient could be transferred to her refer-
ral hospital and the initial outcome was uneventful. Five days 
later, she was discharged on dual antiplatelet high-dose regi-
men (ASA 300 mg per day and clopidogrel 150 mg per day). 
Before discharge, she received intensive counseling on the 
need for compliance with medication, and on secondary 
prevention to avoid further thrombotic events.
Discussion
Numerous reports describe the occurrence of acute 
( 24 hours), subacute ( 30 days), late ( 30 days), and 
very late ( 12 months) stent thrombosis after DES implan-
tation.1,2 However, the true incidence of stent thrombosis 
may be underestimated in clinical trials and could occur 
at substantially higher rates in the real world, where more 
complex lesions are treated.3,4 Several factors that contribute 
to stent thrombosis have been recognized, such as procedure-, 
patient-, and lesion-related factors, thrombogenity of the 
stent, impaired re-endothelization, and antiplatelet therapy 
(Table 1). In recent years, aggressive antiplatelet therapy 
during PCI, including use of ASA, thienopyridines, and 
glycoprotein IIb/IIIa inhibitors, has reduced the risk of 
post-procedural thrombotic complications.5 Nonetheless, the 
incidence of acute stent thrombosis remains approximately 
0.5%–2%.
In our case, the simultaneous thrombosis of both stents 
suggested a systemic disturbance, to which many factors 
might have contributed. Among the procedure-related 
factors, smaller ﬁ  nal lumen dimensions, especially with 
stent malapposition and/or underexpansion appear to be 
important for the development of in-stent thrombosis.6 These 
procedural problems are more important with DES, in which 
the stent length, stent underexpansion, and residual stenosis 
have been associated with risk for stent thrombosis.7 These 
problems, which may be involved in both bare metal and 
DES thromboses, can be prevented during the intervention by 
means of judicious stent deployment and implantation. Good 
selection of the stent size, proper coverage of the entire lesion 
length, and the achievement of good expansion of the stent 
are mandatory during PCI. Technical difﬁ  culties encountered 
during recanalization of the current thrombosed stent in the 
RCA suggested both underexpansion and incomplete stent 
apposition which, with the small stent size (2.5 mm), may 
have been involved in the pathogenesis of the thrombosis. 
Furthermore, stent size in the LAD was also small (2.25 mm). 
It is worthwhile considering other potential concomitant 
factors such as resistance to antiplatelet therapy (clopidogrel 
and/or ASA), compliance to therapy (which plays a major 
role in this case), and the grade of inﬂ  ammation. Antiplatelet 
resistance and inﬂ  ammation are known determinants of 
accelerated atherosclerosis in diabetics.8
Certain stent designs and materials may predispose to 
thrombogenity. Thus the open-cell stent, compared with the 
Table 1 Factors implicated in pathophysiology of in-stent thrombosis
Procedure-related factors
Stent malapposition and/or underexpansion
Stent length, multiple stent
Persistent coronary blood ﬂ  ow
Positive remodelling
Dissections
Residual stenosis
Late stent malapposition due to thrombus
Patient-related factors
Low-ejection fraction
Diabetes mellitus
Advanced age
Renal failure
Variability to wound healing
Antiplatelet therapy discontinuation
Lesion-related factors
Acute coronary syndromes
Bifurcations
In-stent restenosis lesions
Antiplatelet therapy
Discontinuation of antiplatelet therapy
Hyporesponsiveness
Stent factors
Design of stent (open-cell vs closed-cell)
Strut thickness
Polymer type
Drug of drug-eluting stents (lipophility)
Impaired re-endothelialization
Adapted from Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and 
coronary thrombosis: biological mechanisms and clinical implications. Circulation. 
2007;115:1051–1058.Vascular Health and Risk Management 2009:5 104
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closed-cell, appeared to generate greater platelet activation 
during the 30 days after implantation in one study.9 Strut 
thickness, and polymer type and thickness, may also play 
an important role. Nonerodable polymers of the Cypher 
and Taxus provoke chronic eosinophilic inﬁ  ltration of the 
arterial wall, suggestive of hypersensitivity reactions in a 
small number of cases.10 Furthermore, drugs eluted from DES 
may exert a prothrombotic effect. Rapamycin (sirolimus), for 
example, may increase both thrombin- and tumor necrosis 
factor-α-induced endothelial tissue factor expression and 
activity.11 At the same time, paclitaxel enhances tissue factor 
expression and activity in endothelial cells.12 In addition, 
both drugs may easily penetrate into the artery wall owing to 
their lipophylic properties, with chronic retention of the drug 
in the surrounding artery tissue, which may also contribute 
to the prothrombotic environment after DES deployment.13 
Another contributing factor may be the delayed or impaired 
endothelialization of DES. In vitro rapamycin and paclitaxel 
can inhibit proliferation and migration of vascular smooth 
muscle cells, and may also suppress endothelial cells.14
Other factors that may inﬂ  uence the healing are likely to 
be lesion-related, such as primary stenting in acute MI due 
to the presence of a pronounced inﬂ  ammatory and thrombo-
genic environment of the exposed necrotic core to ﬂ  owing 
blood, accompanied by enhanced platelet reactivity,3,15 and 
patient-related, such as antiplatelet therapy discontinuation, 
renal failure, DM, and a lower ejection fraction, which have 
all been reported in clinical studies.3 In particular, discon-
tinuation of antiplatelet therapy has been observed to be 
strongly associated with DES thrombosis.1 The appropriate 
duration of the long-term antiplatelet regimen for prevention 
of DES thrombosis still needs to be assessed in randomized 
prospective trials. A further problem has emerged: hypo-
responsiveness to antiplatelet therapy by some groups of 
patients, in particular diabetic patients.16 Patients with DM are 
characterized by a prothrombotic status, related to endothelial 
dysfunction, impaired ﬁ  brinolysis, increased coagulation 
factors, and increased platelet reactivity and turnover.17,18 
Despite the clinical beneﬁ  t achieved with antiplatelet agents, 
these patients continue to have an increased risk of ischemic 
events compared with nondiabetics.19 Diabetic patients also 
have reduced responsiveness to oral antiplatelet therapy, 
either ASA or clopidogrel,20–22 which is potentially related 
to the need for insulin therapy.23 In particular, the hypore-
sponsiveness to clopidogrel may be partially averted with a 
high dose of clopidogrel (150 mg/day).24,25
In conclusion, our patient presented several factors that 
fostered bad synergies. Her diabetes could have heightened 
platelet reactivity. In this milieu, the early suspension of ASA 
might act as a precipitating factor in a setting of potential 
under-expansion and small DES. The involvement of both 
coronary arteries supports the systemic activation of the 
thrombotic state. Good stent selection and proper implanta-
tion may prevent many stents from being thrombosed in 
prothrombotic environment.
Limitations
Unfortunately, the patient was on infusion of IIb/IIIa antago-
nists, so that platelet function could not be measured with 
optical aggregometry. Moreover, the discussion on the prob-
able underexpansion or malapposition of the thrombosed 
stent based on the technical difﬁ  culties encountered during 
the coronary angioplasty can only be considered a hypothesis. 
To demonstrate this issue intravascular ultrasound should 
have been performed.
Diabetes mellitus: a prothrombotic 
state. Implications for outcomes 
after coronary revascularization
Introduction
Diabetes mellitus (DM) affects 150 million people world-
wide. In particular, type 2 DM is endemic and the incidence 
is increasing.26 The leading cause of disability and prema-
ture mortality among diabetics is cardiovascular disease.27 
DM increases the risk for coronary heart disease, stroke, 
and peripheral arterial disease from 2-fold to 4-fold.28,29 
The increased risk is independent of and in addition to 
other cardiovascular risk factors.30 Importantly, the risk of 
myocardial infarction (MI) is 3- to 5-fold higher in type 
2 DM. A diabetic subject with no history of MI has the same 
long-term risk as a non-DM subject with a past history of 
MI. Patients with DM usually show a diffuse and severe 
coronary artery disease. Coronary artery revascularization 
of diabetics continues to be a challenge: these patients suffer 
from a higher rate of repeated revascularization and worse 
outcomes after PCI, compared with non-DM patients. The 
increased atherothrombotic risk in DM patients is related to 
their pro-inﬂ  ammatory and prothrombotic status. Platelets 
from diabetic subjects show increased adhesiveness and 
an exaggerated aggregation. Reduced responsiveness of 
diabetic patients to antiplatelet therapy has also been docu-
mented. The introduction of DES has improved outcomes 
in diabetic patients. Although DES are now widely used, 
only limited data are available for systematic evaluation of 
their safety in this speciﬁ  c population. Importantly, recent Vascular Health and Risk Management 2009:5 105
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data have raised concerns about increased risks of stent 
thrombosis (ST) and mortality over longer periods of follow-
up. This review focuses on the mechanisms leading to the 
prothrombotic status which characterizes DM patients, and 
its implications for coronary revascularization outcomes, 
including stent thrombosis, in particular antiplatelet therapy 
responsiveness and possible alternatives to improve clinical 
outcomes.
Diabetes: a prothrombotic state
DM is associated with an increased atherothrombotic risk. 
Patients with DM and coronary artery disease show a high 
rate of recurrence after MI.16 Atherothrombotic disease is 
accelerated in subjects with type 1 and type 2 DM, accompa-
nied by diverse underlying mechanisms, despite the common 
trace of hyperglycemia. The main feature of type 2 DM is 
insulin resistance, which precedes the development of hyper-
glycemia.31 In contrast, in type 1 DM, hyperglycemia is the 
dominant abnormality with insulin resistance appearing in 
longer standing patients who develop renal disease.32 Insulin 
resistance and hyperglycemia have several important effects. 
altering coagulation and platelet function, contributing to a 
prothrombotic status.
Insulin resistance determines increased levels of the 
ﬁ  brinolytic inhibitor, Plasminogen Activator Inhibitor-1 
(PAI-1), the link between type 2 DM and ﬁ  brinolysis sup-
pression.33 Furthermore, insulin resistance is associated with 
the increased expression and production of different coagu-
lation factors promoting platelet adhesion to the vascular 
sub-endothelium.34
Insulin resistance affects the cellular phases of hemo-
stasis, also impairing endothelial and platelet function, and 
endothelial-dependent vasodilatation.35–37. Platelet function is 
regulated by insulin38,39 which in normal conditions antago-
nizes the effect of a number of agonists;40 the adhesion or 
aggregation of platelets is upregulated in insulin-resistant 
subjects.17,41 Up-regulation of the P2Y12 ADP receptor 
signaling pathway has been shown in type 2 DM platelets, 
thus contributing to increased platelet reactivity in these 
patients.16
The effect of insulin resistance on the function of platelets 
is related to levels of intracytosolic calcium, a mediator of 
platelet activation.42 Insulin decreases the intracellular con-
centration of calcium in platelets of insulin-sensitive subjects 
in vivo and in vitro, and appears to increase the intra-platelet 
calcium concentrations in insulin-resistant subjects, promot-
ing platelet aggregation and activation.43
Hyperglycemia in turn affects platelet and endothelial 
function, participating in the prothrombotic status of these 
patients. Protein glycation and the formation of advanced gly-
cation end (AGE) products seem to be the underlying mecha-
nisms.44 Endothelial alterations lead to increased production 
of tissue factor,44 a strong pro-coagulant, and alterations in 
soluble coagulation and ﬁ  brinolytic factors. Hyperglycemia 
provokes platelet hyperreactivity and enhanced thromboxane 
biosynthesis. Moreover, glycation of platelet membrane pro-
teins may cause the enhanced expression of receptors such 
as P-selectin and glycoprotein IIb/IIIa, facilitating platelets 
interactions. Furthermore, hyperglycemia provokes nonen-
zymatic glycation of low density lipoprotein (LDL) and very 
low density lipoprotein (VLDL) which in turn may induce 
platelet dysfunction45 (Table 2).
The general inﬂ  uence of platelets abnormalities in DM 
results in hypersensitivity of diabetic platelets to agonists. 
Indeed platelets in diabetic subjects appear to be in an 
activated state even in the absence of vascular injury, and 
respond more frequently even to subthreshold stimuli, as 
evidenced by greater expression of the ﬁ  brinogen-binding 
glycoprotein IIb/IIIa receptor, which constitutes the ﬁ  nal 
common pathway of platelet activation and allows for cross-
linking of individual platelets by ﬁ  brinogen molecules, and 
formation of thrombus.46
Current antiplatelet therapy options
The complexity of platelet activation and subsequent 
aggregation provides many potential sites for inhibition. 
Three classes of platelet-inhibiting drugs, ASA, thieno-
pyridines and platelet glycoprotein IIb/IIIa inhibitors, are 
most commonly used to prevent and to treat disorders of 
arterial vascular thrombosis, with different mechanisms 
Table 2 Insulin resistance and hyperglycemia effects on ﬁ  brinolysis, coagulation, and platelet function
Fibrinolysis Coagulation Platelets
Insulin resistance
↑ PAI-1 ↑ FVII, vWF, FVIII ↓ Insulin-induced regulation
Hyperglycemia/AGE
↑ PAI-1, altered balance PAI-1/tPA ↑ TF, altered expressions FVII, FXII Hyperreactivity, ↑ TX sensitivity/productionVascular Health and Risk Management 2009:5 106
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of action. ASA inhibits thromboxane-A2 (TXA2) production; 
thienopyridines, clopidogrel and ticlopidine, antagonize 
ADP-induced activation; and GPIIb/IIIa receptor antago-
nists (abciximab, tiroﬁ  ban, and eptiﬁ  batide) prevent platelet 
ﬁ  brinogen binding (Figure 3). The mechanism of action of 
ASA and thienopyridines and the role of DM in antiplatelet 
therapy resistance will now be discussed.
Aspirin
ASA is more than 100 years old and provides marked beneﬁ  ts 
in the primary and secondary prevention of coronary, cerebral, 
and peripheral vascular disease.47 ASA inhibits TXA2 produc-
tion by acetylating a serine residue at position 529 within the 
active site of the enzyme cyclo-oxygenase.48 Inhibition is irre-
versible and lasts for the lifespan of the platelet (7–10 days).49 
The inhibition of TXA2 production prevents TXA2-mediated 
granule release and aggregation, while aggregation via throm-
boxane- independent mechanisms, such as that induced by 
thrombin or elevated shear stress, can still occur. It is the 
ﬁ  rst antiplatelet agent of choice for secondary prevention of 
ischemic events in patients with atherothrombotic disease, 
including patients with DM. The American Diabetes Asso-
ciation (ADA) recommends the use of ASA as a secondary 
prevention measure in diabetic patients with atherosclerotic 
disease.50 This recommendation is supported by data from two 
large meta-analyses of major secondary prevention trials by 
the Antithrombotic Trialists’ Collaboration.47,51
The use of ASA in primary prevention in the general 
population is still somewhat controversial, although experts 
agree on its usefulness for primary prevention in patients 
with DM. The ADA recommends 81–325 mg/day of enteric-
coated ASA as a preventive strategy in high-risk diabetic 
individuals, deﬁ  ned by these risk factors:50
•  family history of coronary artery disease
• cigarette  smoking
• hypertension
• weight   120% of ideal body weight
•  micro- or macroalbuminuria
• total  cholesterol    200 mg/dL (LDL cholesterol  100, 
HDL cholesterol   55 in women and   45 in men, and 
triglycerides   200)
The American Heart Association (AHA) has issued 
similar guidelines and recommends 75–160 mg/day of ASA as 
primary prevention in high-risk individuals, deﬁ  ned as those 
with a 10-years risk of coronary artery disease over 10%.52
The Primary Prevention Project evaluated low dose 
ASA (100 mg/day) for the prevention of cardiovascular 
events in almost 4500 individuals with one or more risk 
factors: it showed that after a mean follow-up of 3.6 years, 
ASA reduced the frequency of cardiovascular death and total 
cardiovascular events.53 In a larger population (n = 22,701) 
of healthy men including 533 diabetics, the US Physicians’ 
Health Study found a signiﬁ  cantly lower incidence of MI 
among DM subjects on ASA therapy than among those on 
placebo therapy.54 These results are also supported by the 
Early Treatment Diabetic Retinopathy Study (ETDRS), 
which enrolled type 1 and type 2 diabetic men and women, 
about 48% of whom had a history of cardiovascular disease. 
This study, a primary and secondary prevention trial, showed 
that the relative risk of MI in the ﬁ  rst 5 years in those ran-
domized to ASA therapy was signiﬁ  cantly lower than those 
randomized to placebo.55 Finally, the Hypertension Optimal 
Treatment (HOT) study, which examined antihypertensive 
treatment in 18,790 individuals, 1501 of whom had DM, 
showed that ASA therapy resulted in an additional 15% 
reduction in the risk of cardiovascular events over that seen 
with antihypertensive therapy.56 These studies support the 
aforementioned AHA guidelines.
ASA “resistance”
Despite the use of ASA, a high percentage of patients still 
suffer from atherothrombotic complications, giving rise 
to the concept of “ASA resistance”. Various studies have 
validated the relationship between ASA resistance and 
the risk of ischemic events. However, the deﬁ  nition of 
the ASA resistance phenomenon remains controversial. 
Strictly speaking, “resistance” is deﬁ  ned as the failure of 
a speciﬁ  c antiplatelet agent to inhibit its target. Thus ASA 
resistance should be deﬁ  ned as the failure of ASA to block 
arachidonic acid-induced platelet aggregation, inhibiting 
production of platelet thromboxane A2.57 In the scientiﬁ  c 
literature, the term resistance has been applied to failure to 
prevent occurrence of atherothrombotic vascular events in 
patients taking ASA (or other antiplatelet agents). However 
this phenomenon should more appropriately be deﬁ  ned 
as “therapeutic failure”.58 Indeed numerous pathways are 
involved in thrombotic events, which therefore cannot be 
explained by inadequate inhibition of that target of an indi-
vidual antiplatelet agent. Several laboratory assays have 
been used to explore for ASA resistance. Moreover, many 
of the currently available assays are also sensitive to other 
variables; inter-test correlations have seldom been reported, 
resulting in uncertainty about the capacity of these tests to 
detect ASA failure to the extent comparable with that of 
optical aggregation, considered by many experts to be the 
gold standard (Table 3). This uncertainty may explain why Vascular Health and Risk Management 2009:5 107
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the reported range of ASA resistance varies broadly, from 
5% to 40%, depending on the assay used for identiﬁ  cation 
and the population studied.59–61 Various reports have shown 
that when responsiveness to aASA is assessed using COX-1 
speciﬁ  c assays, resistance to ASA is virtually absent, which 
is primarily the result of patient noncompliance with treat-
ment.62 The redundancy of platelet activation pathways and 
receptors, not inhibited by ASA, contribute to the presence 
of variability of ASA-induced antiplatelet effects when 
using non-COX-1 speciﬁ  c assays. More speciﬁ  cally, path-
ways involving non-TXA2-dependent activators such as 
thrombin, ADP, epinephrine, and collagen can bypass the 
ASA-mediated inhibitory effect leading to platelet activation 
and thrombosis.63 Catecholamine-induced platelet aggrega-
tion is one such pathway that might not be adequately inhib-
ited by ASA. Among patients with a previous MI, ASA has 
reportedly achieved adequate antiplatelet effects at rest, but 
failed to inhibit exercise-induced increases in platelet aggre-
gation.64 Similarly, stimulation of P2Y1/P2Y12 receptors by 
ADP, of α2β1 integrin and GPVI by collagen, and of PAR1/
PAR4 receptors by thrombin on platelet membrane, leads to 
platelet activation in spite of adequate COX-1 inhibition.65 
All these pathways are increased in DM patients, because 
of a greater prevalence of ASA “resistance” when assessed 
Table 3 Tests used to evaluate antiplatelet effect of ASA
Test Method Comment
TXB2 concentration in serum 
or urine
Measurement of serum TXB2 or urinary d-TXB2 
levels by radioimmunoassay or ELISA
TXA2 has a short half-life in serum and is rapidly 
converted into a stable matebolite, TXB2
Bleeding time For study of the natural hemostasis; usually 
performed with a disposable template device; the 
test is based on the time necessary for bleeding 
to stop following incisions in the skin of the 
forearm
Nonspeciﬁ  c and insensitive, poorly reproducible 
and invasive; inﬂ  uenced by depth, location, direc-
tion of incisions, skin thickness, and skills 
of the technician performing the test; rarely 
used to assess platelet function
Flow cytometry Using antibodies, measurement of common 
platelet activation markers such as: 
–   Granule membrane markers (p-selectin, CD63, 
CD40L, etc)
–   Activation-dependent changes in GP IIb/IIIa 
complex conformation (PAC-1, etc)
Very powerful technique; uses whole blood, 
but requires expensive equipment/reagent and 
manipulation by experienced technician
Thromboelastography Analysis of the clot’s physical property (strength) 
form formation to lysis, as an agonist is added 
(classically arachidonic acid or adenosine 
diphosphate)
Uses whole blood; easy and rapid to use; 
controversy as to correlation with classic 
aggregometry
Aggregometry
1)   Classic platelet aggregometry 
(optical aggregation, light 
transmission analysis, classical 
turbidimetric aggregometry)
2) Whole blood aggregometry
Analysis of light transmission as an agonist 
(classically arachidonic acid or adenosine 
diphosphate) is added to platelet rich plasma to 
provoke platelet aggregation 
Analysis of electrical impedance between two 
electodes immersed in whole blood in the pres-
ence of a platelet aggregation agonist (classically 
arachidonic acid or adenosine diphosphate)
Assay well estabilished in the literature; time 
and labor consuming, requiring manipulation of 
sample by an experienced technician; removal 
of other blood elements forbids study of their 
inﬂ  uence on platelet aggregation
Used to study the inﬂ  uence of whole blood 
constituents on platelet aggregation; time con-
suming, requiring manipulation by experienced 
technicians
Platelet function analyzers
1) Platelet  function  analyzer (PFA-100®)
2)   Rapid platelet function assay-ASA 
(RPFA-ASA, Verify Now Aspirin®)
Assessment of platelet aggregation under high 
shear: whole blood is aspirated through a small 
aperture cut in a membrane coated with type 1 
collagen and either epinephrine or adenosine 
diphosphate; the time necessary for the 
formation of a hemostatic plug to occlude 
the aperture is recorded 
The test cartridge contains a preparation of 
human ﬁ  brinogen-coated beads and a platelet 
agonist; as blood is inserted into cartridge, 
platelet agglutinate and form aggregated, which 
increases light transmittance
Intend to imitate plug formation after injury 
to a small vessel wall under normal ﬂ  ow 
conditions; easy and rapid to use; controversy as 
to correlation with classic aggregometry; very 
expensive 
Speciﬁ  cally developed for the detection of 
platelet dysfunction in whole blood due to ASA 
ingestion; easy and rapid to use; controversy as 
to correlation with classic aggregometry; very 
expensiveVascular Health and Risk Management 2009:5 108
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with non-COX-1 specific assays.66–68 The concomitant 
administration of commonly used analgesics may modulate 
the effect of low-dose ASA. A clinical dosing regimen of 
ibuprofen may competitively inhibit the sustained inhibitory 
effect of COX-1 on platelets.69 An imbalance between oxi-
dants and antioxidants has also been suggested as an inﬂ  uence 
on aASA reactivity: Cipollone and colleagues demonstrated 
that increased nonenzymatic formation of isoprostanes, 
particularly F2-isoprostanes like 8-iso-PGF2α, may provide 
an important biochemical link between an altered oxidant/
antioxidant balance and ASA-insensitive TX biosynthesis in 
patients with unstable angina.70
The role of genetics in a patient’s response to aASA is 
controversial, because polymorphisms of platelet membrane 
glycoproteins71 of von Willebrand factor or of the collagen 
receptor gene have been associated with ASA resistance.72 
How the concomitant presence of diabetes and these genetic 
polymorphisms affects the prevalence of ASA resistance 
remains unknown.
With all these limitations, subgroups of DM patients 
have been considered clinically unresponsive to the cardio-
protective effects of ASA. The Heart Outcomes Prevention 
Evaluation trial, for example, demonstrated a 50% higher 
rate of cardiovascular events in those with, compared with 
those without, DM despite ASA therapy.73 In the Primary 
Prevention Project, ASA use was not associated with cardio-
vascular protection in those with DM, but a 40% decrease in 
cardiovascular death in those without.74
Thienopyridines
Thienopyridines are orally-active antagonists of the platelet 
ADP (P2Y12) receptor.75 Clopidogrel and ticlopidine are the 
two currently available thienopyridines, although clopidogrel 
is the thienopyridine of choice because it has a more favor-
able safety proﬁ  le than ticlopidine.76 The antiplatelet effects 
of thienopyridines are irreversible due to the formation of a 
disulﬁ  de bond with the receptor and last for the lifespan of 
the platelets. They are inactive prodrugs that are converted 
by the hepatic cytochrome P450 system into an active thiol 
metabolite, which interacts with the P2Y12 receptor, in an 
inactive carboxy metabolite. These agents are of beneﬁ  t in 
coronary, peripheral, or cerebrovascular atherosclerosis, and 
their combination with ASA is routine in patients undergoing 
PCI and in patients with acute coronary syndromes.77–79 
Current guidelines for the management of unstable angina 
and non-ST elevation MI (NSTEMI) recommend promptly 
adding clopidogrel to ASA in patients presenting with these 
clinical syndromes.30 Furthermore, clopidogrel should be 
used in patients being treated with medical therapy or coro-
nary revascularization for up to 9–12 months. Current guide-
lines also recommend administering clopidogrel to patients 
who are hypersensitive or intolerant to ASA.77 Clopidogrel 
has also been approved recently by the US Food and Drug 
Administration for patients with STEMI, based on the results 
of two large-scale clinical trials.77,80,81
The CAPRIE (Clopidogrel versus ASA in Patients at 
Risk of Ischemic Events) trial was a randomized, blinded 
trial, involving more than 19,000 patients, designed to assess 
the relative efﬁ  cacy of clopidogrel and ASA in reducing the 
risk of a composite outcome cluster of ischemic stroke, MI, 
or vascular death.82 A retrospective analysis of the CAPRIE 
study showed, for the ﬁ  rst time, the superiority of clopidogrel 
compared with ASA in the diabetic subgroup. This superi-
ority was attributed to the more potent antiplatelet effect of 
clopidogrel, and its more efﬁ  cient inhibition of hyperreactive 
diabetic platelets: only 15.6% of diabetic patients on clopido-
grel therapy developed the composite vascular primary end-
point vs 17.7% of those on ASAtherapy alone (p = 0.042); the 
insulin subgroup showed greater absolute reduction.81,83,84
The Clopidogrel in Unstable Angina to Prevent Recurrent 
Events (CURE) trial evaluated the efﬁ  cacy and safety of 
clopidogrel when given with ASA to patients suffering from 
acute coronary syndromes, without ST-segment elevation 
for 3 to 12 months (n = 12562).52 In this trial, the rate of 
primary outcome (composite vascular death, MI or stroke) 
was much higher in the diabetic cohort of patients. The use 
of clopidogrel in this subgroup reduced the rate of this end-
point (14.2% rate of primary end-point in diabetic cohort on 
clopidogrel vs 16.7% in diabetic cohort on placebo) without 
it reaching statistical signiﬁ  cance.79 The high event rates may 
in part be attributed to the persistence of increased platelet 
reactivity in DM patients even when on dual antiplatelet 
therapy compared with non-DM patients.
Clopidogrel response variability
The methodology most commonly reported in the literature 
to measure clopidogrel response is conventional light trans-
mittance aggregometry, in which platelet-rich plasma is 
prepared from blood usually anticoagulated with citrate and 
then stimulated with ADP.85 Notably, the degree of platelet 
responsiveness in patients treated with clopidogrel has been 
found to follow a normal bell curve.85,86 The concept of 
variability in response to clopidogrel has long been recog-
nized during investigations of platelet reactivity, especially 
after elective coronary stent implantation.87 Several studies 
investigated the use of a 300 mg loading dose of clopidogrel Vascular Health and Risk Management 2009:5 109
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immediately after stenting and found highly variable 
responses among individuals.88–90 Although higher loading 
dose regimens are associated with better and faster response 
proﬁ  les, a broad variability in the antiplatelet effects contin-
ues to be observed.91,92 The durability of platelet inhibition 
by clopidogrel has also been studied showing the sustained 
antiplatelet effect of clopidogrel after 5 days, but also a 
signiﬁ  cant heterogeneous response to the medication.93 Thus 
the antiplatelet effects after both the acute and chronic phases 
of clopidogrel therapy vary.86 Importantly, increased rates of 
coronary stent thrombosis and recurrent ischemic events after 
PCI, have been noted in poor clopidogrel responders. Vari-
ability in clopidogrel response is a multifactorial process, in 
which clinical, cellular, and genetic factors are involved.86 
Among the clinical factors, DM has been associated with a 
greater prevalence of poor responsiveness.16 In particular, 
diabetic patients have been shown to have a poor response to 
clopidogrel in both the acute and chronic phases of therapy.67 
Of note, insulin-requiring diabetics are those who persist 
with the strongest platelet reactivity despite dual antiplatelet 
therapy.23 DM patients usually have a poor response to dual 
antiplatelet therapy, but a variety of antiplatelet effects has 
also been observed in these patients.67 Recent ﬁ  ndings have 
shown that enhanced platelet reactivity selectively deter-
mined in DM patients, enables identiﬁ  cation of those with a 
greater long-term risk of atherothrombotic events.19
Overall, the persistence of elevated platelet reactivity, 
and reduced response to ASA and clopidogrel therapy, 
enhance the atherothrombotic risk of DM patients. Multiple 
causes have been suggested. Poor glycemic control is an 
important cause of increased platelet reactivity18,23,94 In this 
way, platelet reactivity can be reduced with tight control of 
glucose levels.95 Other mechanisms intrinsic to the diabetic 
platelet, which involve intracellular signaling pathways, 
play a critical role in platelet reactivity. These may include 
increased oxidative stress leading to enhanced peroxidation 
of arachidonic acid to form biologically active isoprostanes,18 
increased platelet turnover,67 increased cytosolic levels of 
calcium,96,97 insulin resistance, and upregulation of the P2Y12 
pathway.67,98
Treating ASA and clopidogrel resistance
The treatment for failed antiplatelet therapy, especially in 
diabetic patients, is as yet undeﬁ  ned. Initially, physicians 
should ensure patient compliance, and minimize drug–drug 
interactions. In diabetic patients, physicians must also estab-
lish optimal control of glucose levels, cholesterol levels, and 
blood pressure, thus minimizing platelet reactivity.
The optimal dose is controversial. There is no good 
evidence to date that increasing the ASA dose would be 
useful, especially because of an increased risk of bleeding.99 
Of note, increasing the dose of ASA is not associated with 
further inhibition of COX-1.99 Increasing the loading or 
maintenance doses of clopidogrel may be an option.25,99 
Increasing the loading dose increases drug responsive-
ness and has been associated with improved clinical out-
comes.100,101 This approach is valid only for the acute phase 
of treatment, however, because patients must rely on daily 
maintenance therapy for long-term prevention of ischemic 
events. The Optimizing Antiplatelet Therapy in Diabetes 
Mellitus (OPTIMUS) study evaluated the functional impact 
of a 150-mg maintenance dose of clopidogrel compared with 
a standard 75-mg dose selectively in type 2 DM patients with 
a suboptimal response to standard dose therapy. High main-
tenance therapy was associated with enhanced antiplatelet 
effects compared with the 75-mg dose.25 Although a high 
dose resulted in marked platelet inhibition, many patients 
remained above the therapeutic threshold of post-treatment 
platelet reactivity used in this study, suggesting the need 
for alternative antithrombotic regimens in these high-risk 
patients. This issue has prompted recent interest in triple 
antiplatelet therapy in DM patients, using cilostazol in addi-
tion to ASA and clopidogrel. Triple therapy has been shown 
to be associated with a reduced risk of stent thrombosis.102,103 
In the bare metal stent (BMS) era, triple therapy was shown 
to be beneﬁ  cial for high risk patients, including diabetics, 
in reducing restenosis rates.102 In the DES era, recent ﬁ  nd-
ings from the DECLARE-DIABETES study showed triple 
therapy to be associated with reduced target lesion revascu-
larization (TLR) and major adverse cardiac events (MACE) 
at 9 months.104 The mechanisms underlying this beneﬁ  t may 
arise from the greater antiplatelet effects achieved, as well 
as the effects of cilostazol on endothelial cells and smooth 
vascular muscle cells. The OPTIMUS-2 study evaluated the 
functional impact of adding cilostazol to ASA and clopido-
grel therapy in type 2 DM patients. The study showed that 
cilostazol compared with placebo was associated with marked 
inhibition of P2Y12 signaling.105 Current guidelines specify a 
class IIb indication with a level of evidence C that the dose 
of clopidogrel can be increased to 150 mg per day if  50% 
inhibition of platelet aggregation is demonstrated only in 
patients in whom stent thrombosis may be catastrophic or 
lethal (such as unprotected left main, bifurcating left main 
and last patent coronary vessel).106 However, although the 
use of a 150-mg maintenance dose of clopidogrel in patients 
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shown to be associated with enhanced antiplatelet effects, 
these effects are nonuniform and many patients persist with 
inadequate platelet inhibition.107 Probably the use of more 
potent P2Y12 inhibitors, with their uniform and potent effect, 
could help us resolve this problem. Prasugrel is a third-
generation P2Y12 inhibitor, with more potent and less variable 
antiplatelet effects compared with clopidogrel.108,109 Recently, 
the TRITON-TIMI 38 (Trial to Assess Improvement in Ther-
apeutic Outcomes by Optimizing Platelet Inhibition with Pra-
sugrel-Thrombolysis in Myocardial Infarction) trial showed 
signiﬁ  cantly reduced rates of ischemic events, including 
stent thrombosis, in patients presenting with acute coronary 
syndromes undergoing PCI treated with prasugrel compared 
with clopidogrel.110 The net clinical beneﬁ  t achieved with 
prasugrel in the general study population still has statistical 
signiﬁ  cance for better clinical outcomes although diminished 
by an increased risk of bleeding. Importantly, in this trial the 
greatest risk reduction (rate of primary end-point, deﬁ  ned as 
death from cardiovascular causes, nonfatal MI or nonfatal 
stroke, in diabetic patients on prasugrel 12.2% vs diabetic 
patients on clopidogrel 17.0% with 30% relative risk reduc-
tion) was observed in the diabetic population (n = 3146). 
Importantly, in these patients prasugrel was not associated 
with an increased risk of major bleedings compared with 
clopidogrel. The functional impact of prasugrel vs clopi-
dogrel among selected diabetic patients is currently being 
evaluated in the OPTIMUS-3 study.
Percutaneous coronary revascularization 
in diabetics
Diabetic patients have more progressive, diffuse, and mul-
tivessel coronary disease compared with nondiabetics,111,112 
and have been shown to have worse outcomes after both PCI, 
especially with BMS, and surgery, compared with nondiabetic 
patients.113 This prognosis includes a 35% to 45% higher inci-
dence of TLR and a 33% to 86% higher incidence of angio-
graphic restenosis compared with nondiabetic patients with 
BMS.113,114 The advent of DES has completely changed the 
scenario of percutaneous revascularization in diabetic patients. 
Most clinical experience with DES comes from the Cypher® 
(sirolimus) and Taxus® (paclitaxel) stents, introduced in 2002 
and 2003, respectively. Compared with BMS, the ﬁ  rst genera-
tion DES signiﬁ  cantly reduced restenosis rates and MACE, and 
show signiﬁ  cantly lower rates of TLR, target vessel revascu-
larization (TVR) and target vessel failure (TVF).8,115
Despite the routine use of DES in diabetic patients, only lim-
ited data are available for systematic evaluation of their long term 
safety in this population. Most of the data come from published 
subgroup analysis of randomized trials between DES and BMS, 
and registry data from single or multiple centers.115 Five studies, 
that is, DIABETES,116 ISAR-DIABETES,117 a recently pub-
lished head-to-head comparison of sirolimus-eluting stent (SES) 
and paclitaxel (PES)-eluting stent in 120 diabetics patients,118 
the SCORPIUS Trial,119 and the DESSERT Study,120 focused 
solely on diabetics (Table 4).
The DIABETES116 (Diabetes and Sirolimus-Eluting 
Stent) trial is a multicenter, randomized, placebo-controlled 
trial involving 160 diabetic patients, 80 of whom were treated 
with BMS and 80 with SES. Late lumen loss (LLL) assessed 
by QCA at 9 month follow-up was the primary end-point. 
The SES treated group showed a signiﬁ  cant reduction of 
LLL (relative reduction 87%). The study considered a sub-
randomization according to the type of diabetes; the SES 
beneﬁ  t was independent from diabetes status. The study also 
demonstrated similar repeat revascularization rates among 
both insulin- and noninsulin-treated diabetics; and conﬁ  rmed 
the relationship between glycemic control and progression 
of atherosclerosis. These results with SES have recently 
been conﬁ  rmed by two trials especially designed for diabetic 
patients: the SCORPIUS Trial119 and the Italian Multicenter 
Randomized DESSERT Study.120
The ISAR (In-Stent Angiographic Restenosis)-
DIABETES117 a prospective trial, was designed to show 
the noninferiority of the PES compared with SES, deﬁ  ned 
as a difference in the extent of in-segment LLL of no more 
than 0.16 mm, at 6–8 months follow-up. The study included 
250 diabetic patients randomized to receive SES (n = 150) or 
PES (n = 150). It found that the use of SES in diabetics was asso-
ciated with a decrease in the extent of late loss, in insulin-treated 
(p = 0.02) and noninsulin-treated (p = 0.03) patients, suggesting 
a reduced risk of restenosis, but the study was not sufﬁ  ciently 
powered to assess the incidence of clinical restenosis.
Tomai and colleagues compared the efﬁ  cacy of SES and 
PES in diabetic patients with multiple de novo coronary 
artery lesions, to prevent restenosis.118 They randomized 
60 patients for a total of 120 lesions (SES, n = 60; PES, n = 60) 
and concluded that SES, when directly compared with PES, 
is associated with a decrease in the extent of in-stent LLL at 
8 months, suggesting a reduced risk of restenosis.
Although DES reduces angiographic and clinical reste-
nosis compared with BMS, in late 2006 concerns over DES 
safety emerged. Several studies and meta-analysis suggested 
increases in adverse clinical end-points with DES, especially 
after the ﬁ  rst year of stent implantation.121,122 The overall rate 
of acute and subacute ST (occurring within 24 hours or within 
30 days after stent implantation respectively) appears to be Vascular Health and Risk Management 2009:5 111
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Table 4 Studies performed in diabetic patients treated with DES
Study  Design  and  results
Diabetes117 160 DM patients: 80 BMS
 80  SES.
Primary end point: LLL at 9 month
In-segment LLLwas reduced from 0.470.5 mm for BMS to 0.060.4 mm for SES(P 0.001).
TLR and MACE: 31.3% and 36% in BMS versus 7.3% and 11.3% in SES; both P 0.001). 9-month follow-up 
ST occurred in 2 BMS patients
No ST in SES group
ISAR-DIABETES118 250 DM patients: 150 SES
 150  PES
Noninferiority of the PES vs SES:
Primary end point: difference in LLL of no more than 0.16 mm, at 6–8 months follow-up.
SES associated with a decrease in the extent of LLL in insulin-treated (p = 0.02) and noninsulin-treated 
(p = 0.03) patients.
Tomai and 
colleagues119
60 DM patients, 120 lesions: 60 SES,
 60  PES,
SES associated with a decrease in the extent of in-stent LLL at 8 months, suggesting a reduced risk of 
restenosis.
SCORPIUS120 200 DM patients : 98 SES
 102  BMS
Primary end point: in segment LLL. Secondary: MACE rate at 30 days and 8 and 12 months. LLL in SES was 
0.18 mm; 0.74 mm in BMS. In-segment restenosis: 8.8% SES and 42.1% BMS (p   0.0001). TLR: 5.3% in SES 
and in 21.1% in BMS (p = 0.002) MACE rate 14.7% in SES versus 35.8% in BMS.
DESSERT121   150 DM patients: 75(109 lesions) SES
  75 (109 lesions) BMS.
Primary end point: LLL Secondary: MACE and TVR at 30 days, 9 and 12 months. LLL decreased from 
0.96 +/− 0.61 mm for BMS to 0.14 +/− 0.33 for SES (p   0.001), and in-segment binary restenosis was 
38.8% versus 3.6%, respectively (p   0.001). 12 months MACEs 22.1% versus 40% (p = 0.023), TLR 5.9% 
versus 30% (p   0.001), and TVF 14.7% versus 34.3% (p = 0.008).
no different for DES and BMS, but analysis incorporating 
long-term follow-up has shown a small but ﬁ  nite risk of late 
ST associated with DES. Of note, despite the small increase 
in late ST, overall rates of death and MI are similar between 
DES and BMS.121-124 The magnitude of very late ST is not 
well deﬁ  ned, but is in the range of 0.2%–0.4% excess events 
per year after year 1 through year 4.125,126 Importantly, these 
numbers are from clinical trials and not from real world 
practice, where patients show more complex scenarios.
Surgery remains the gold standard treatment for multivessel 
disease in diabetics. The ongoing CARDIA (Coronary Artery 
Revascularization in DIAbetes) trial127 and the FREEDOM 
(Future REvascularization Evaluation in Patients with Diabetes 
mellitus: Optimal management of Multivessel disease) trial128 
will shed light on the outcomes of DES implantation in diabet-
ics compared with current surgical techniques.
Stent thrombosis in diabetics: incidence 
and predictors
ST with BMS and DES often presents in a catastrophic 
way, by triggering death or acute MI.3,129 The incidence 
of ST could easily be underestimated, because a patient’s 
cause of death is not always determined and angiography 
is not always performed after MI. To control for this pos-
sibility, cases in which patients have experienced sudden 
death or acute MI not deﬁ  nitively proved to be secondary 
to ST have been adjudicated judged as thrombotic events in 
studies examining incidence and predictors of ST.3,129 The 
Academic Research Consortium130 developed consensus 
deﬁ  nitions delineating 3 levels of certainty of ST: deﬁ  nite, 
probable, and possible. Deﬁ  nite ST involves the pathologic 
or angiographic conﬁ  rmation of thrombus within a stent in 
a patient who presents with an acute coronary syndrome. 
Probable ST pertains to any unexplained death within 30 days 
after PCI or any target-vessel acute MI occurring without 
angiographic conﬁ  rmation of a culprit lesion. Possible ST 
includes any unexplained death occurring later than 30 days 
after the index procedure (Table 5). ST is also classiﬁ  ed 
according to time of presentation. Acute ST appears within 
24 hours after PCI; subacute ST presents between 24 hours 
and 30 days; late ST between 1 and 12 months; very late ST 
occurs later than 1 year.Vascular Health and Risk Management 2009:5 112
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Table 5 Academic research consortium deﬁ  nitions of stent thrombosis
Category  Deﬁ  nition
Deﬁ  nite 1.   Angiographic conﬁ  rmation based on Thrombolysis in Myocardial Infarction 
(TIMI) ﬂ  ow and 1 of the following within 48 hours:
 •   New acute onset of ischemic symptoms at rest
 •    New ischemic electrocardiographic changes suggestive of acute ischemia
 •    Typical increase and decrease in cardiac biomarkers as evidence of an 
acute myocardial infarction (MI)
2.   Pathologic conﬁ  rmation of recent ST at autopsy or by tissue examination 
after thrombectomy
Probable 1.   Any unexplained death within the ﬁ  rst 30 days
2.   MI related to acute ischemia in the territory of the implanted stent without 
angiographic conﬁ  rmation of ST and in the absence of any other obvious 
cause at any time after index procedure
Possible Any unexplained death after intracoronary stenting from 30 days after index 
percutaneous coronary intervention until the end of trial follow-up
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A number of factors are associated with DES thrombosis. 
In a series of 2,229 patients, of whom 29 experienced ST, 
risk factors included bifurcation lesions, renal failure, PCI 
in the setting of acute MI and DM.129 The strongest associa-
tion was between ST and the premature discontinuation of 
clopidogrel. The etiology of ST is multifactorial.131 Patient, 
lesion, procedural, and stent characteristics can all play a 
role. Other factors include mechanisms unique to the DES, 
namely, hypersensitivity, inflammatory responses, and 
delayed endothelialization.132 Given that these reactions 
occur predominantly with late ST, the presumed trigger is 
hypersensitivity to the stent polymer, because active drug 
should no longer be present. This phenomenon has not been 
documented with BMS.
The increased risk in diabetic patients might be related to 
the pro-inﬂ  ammatory and pro-thrombotic status typical of this 
population along with the more diffuse and aggressive nature 
of atherosclerosis (longer lesion lengths, smaller vessel size, 
and greater plaque burden) which might lead to less optimal 
procedural results.8,133–135
The nonresponsiveness to antiplatelet therapy also has a 
role: diabetics have been considered clinically unresponsive 
to the cardioprotective effects of ASA and clopidogrel.16 
Patients with ST have high in vitro post-treatment platelet 
reactivity despite the dual antiplatelet treatment, suggesting 
that platelet aggregation nonresponsiveness to clopidogrel 
may be an important cause.136 Buonamici and colleagues137 
assessed whether nonresponsiveness to clopidogrel as 
revealed by high in-vitro post-treatment platelet reactivity 
was predictive of DES thrombosis. In their interesting 
work, a total of 804 patients who had successful SES or 
PES implantation were assessed for post-treatment platelet 
reactivity after a loading dose of 600 mg of clopidogrel. 
Patients with platelet aggregation by 10 μmol adenosine 
5-diphosphate  70% were defined as nonresponders. 
All patients received chronic dual antiplatelet treatment 
(ASA 325 mg and clopidogrel 75 mg daily) for 6 months. 
The primary end-point was the incidence of deﬁ  nite/probable 
early, subacute, and late ST at 6-month follow-up. The inci-
dence of 6-month deﬁ  nite/probable ST was 3.1% (Table 6). 
All ST were subacute or late. Of 804 patients, 105 (13%) were 
not responsive to clopidogrel. The incidence of ST was 8.6% 
in nonresponders and 2.3% in responders (p   0.001). The 
authors concluded that nonresponsiveness to clopidogrel is a 
strong independent predictor of ST in patients receiving SES 
or PES. Moreover in this study, DM was associated with low 
response (overall 169 DM patients: 19% were responders and 
36% nonresponders, p   0.001).
To date, few large-scale studies have focused on very late 
ST, later than 1 year after DES implantation. Speciﬁ  c predic-
tors for late ST have not yet been identiﬁ  ed. Moreover, DES 
thrombosis in randomized trials could not be comparable 
to those observed in clinical practice, frequently including 
off-label indications. Interestingly the Multicenter Spanish 
Registry ESTROFA138 was designed to assess the incidence, 
predictors, and outcome of DES thrombosis (angiography-
documented) in real-world clinical practice, with 3 years 
follow-up. In a total of 23,500 patients treated with DES the 
cumulative incidence of ST was 2% at 3 years. Antiplatelet 
treatment had been discontinued in 95 cases (31.6%). No 
differences in incidences were found among stent types. 
Independent predictors for subacute ST analyzed in a 
subgroup of 14,120 cases were diabetes, renal failure, acute 
coronary syndrome, STEMI, stent length, and left anterior 
descending artery stenting; while predictors for late ST were 
STEMI, stenting in left anterior descending artery, and stent 
length. The authors concluded that patient proﬁ  les differed 
between early and late ST.
Daemen and colleagues121 performed a large multicenter 
cohort study assessing all angiographically documented ST, 
after unrestricted use of SES and PES (8146 patients; SES 
n = 3823; PES n = 4323) between 2002 and 2005. Their 
purposes were to estimate the incidence and time course 
of ST with DES in routine clinical practice; identify pre-
dictors and differences between early ( 30 days) and late 
( 30 days) ST; and assess differences between SES and 
PES. They observed angiographically documented ST in 
152 patients (cumulative incidence at 3 years 2.9%). Early 
ST was noted in 91 (60%) patients, and late ST in 61 (40%) 
patients. Late ST occurred steadily at a constant rate of 0.6% 
per year up to 3 years after stent implantation. Incidence of 
early ST was similar for SES (1.1%) and PES (1.3%), but 
late ST was more frequent with PES (1.8%) than with SES 
(1.4%; p = 0⋅031). At the time of ST, dual antiplatelet therapy 
was being taken by 87% (early) and 23% (late) of patients 
(p   0⋅0001). Independent predictors of overall ST were 
acute coronary syndrome at presentation (HR 2.28, 95% CI 
1.29–4.03) and diabetes (2.03, 1.07–3.83). The results of the 
Table 6 ST classiﬁ  cation according to time of presentation
Acute  24 hr
Subacute  24 hr  30 days
Late  30 days  12 months
Very late  12 monthsVascular Health and Risk Management 2009:5 114
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present study suggest that late ST with DES occurs more 
frequently than expected116 and that rates increase steadily 
during long-term follow-up. The authors suggest that sus-
tained occurrence over a long-term period might be explained 
in part by the delayed healing response after implantation of 
DES. This maybe due to the delayed re-endothelization and 
hypersensitivity reactions to the antiproliferative drugs, or 
more probably, to the synthetic polymers.131,132 This study 
conﬁ  rms the predictive value of diabetes and acute coronary 
syndrome at presentation.
A speciﬁ  c assessment of DES safety in DM has yet to be 
demonstrated. Whether DES are similarly safe and effective 
in the higher risk cohort of diabetic patients remains con-
troversial. Several meta-analysis and registries have been 
performed showing contrasting data.
Kumbhan and colleagues139 conducted a meta-analysis 
including randomized trials comparing either PES or SES 
with a BMS or PES with SES, in diabetic patients during a 
follow-up of a maximum of 12 months. A total of 16 studies 
were identiﬁ  ed, which included 2951 diabetic patients. 
A reduction in target lesion revascularization (TLR) was 
found with DES compared with BMS (RR 0.35, 95% 
CI 0.27–0.46, P   0.001). Similar reductions were noted 
in the incidence of MACE (RR 0.42, 95% CI 0.31−0.56, 
P   0.001), in-segment restenosis (RR 0.31, 95% 
CI 0.25–0.40, P   0.001), and non-Q-wave MI (RR 0.57, 
95% CI 0.32–0.99, P = 0.046). Event rates were similar for 
Q-wave MI (RR 0.72, 95% CI 0.25–2.07, P = 0.54), death 
(RR 0.64, 95% CI 0.32–1.28, P = 0.20), and ST (RR 0.41, 
95% CI 0.13–1.27, P = 0.12).
The speciﬁ  c safety of SES compared with BMS has 
been addressed in a recent meta-analysis by Spaulding 
and colleagues.140 The authors reported greater long-term 
mortality in patients with DM treated with SES compared 
with those treated with BMS, an effect that was absent in 
patients without DM. These data must be interpreted with 
caution: in the studies analyzed, survival among BMS treated 
patients was far better than expected, which may have 
accounted for the observed differences. Besides, spurious 
results due to the modest-sized diabetic cohort (n = 428) 
in this series may be another cause of error. On the other 
hand, the analysis of 1-year data collected by the e-Cypher 
registry 141 suggests a high degree of safety of SES, with a rate 
of ST similar to that observed in randomized trials. Insulin 
treated DM among other factors was recognized as a clinical 
predictor of stent thrombosis at 12 months.
The EVASTENT Matched-Cohort Registry142 assessed 
the frequency and causes of ST speciﬁ  cally in diabetic and 
nondiabetic patients after SES implantation. In this matched 
multicenter cohort registry of 1731 during a 1-year follow-
up, MACE occurred in 78 patients (4.5%), cardiac death in 
35 (2.1%), and stent thrombosis in 45 (2.6%): 30 deﬁ  nite, 
23 subacute, and 22 late, including 9 at 6 months. In 
univariate analysis, the 1-year ST rate was 1.8 times higher in 
diabetic than in nondiabetic patients (3.2% vs 1.7%; log rank 
p   0.03); diabetic patients with multivessel disease experi-
enced the highest rate and nondiabetic single-vessel disease 
patients the lowest (4.3% vs 0.8%; p   0.001). In multivari-
ate analysis, in addition to the interruption of antithrombotic 
treatment, independent ST predictors were previous stroke, 
renal failure, lower ejection fraction, calciﬁ  ed lesion, length 
stented, and insulin-requiring diabetes.
The safety of PES vs BMS has also been assessed. 
Analysis of the ﬁ  ve pivotal PES trials focused speciﬁ  -
cally on the diabetic patient143 demonstrated similar rates 
of death, MI, and ST with both stents at 4-year follow-up. 
Patients treated with PES and BMS had similar baseline 
characteristics among both the diabetic and nondiabetic 
cohorts in these trials. At 4-year follow-up, there were no 
signiﬁ  cant differences between PES and BMS among dia-
betic patients in the rates of death (8.4% vs 10.3%, respec-
tively, p = 0.61), MI (6.9% vs 8.9%, p = 0.17), or ST (1.4% 
vs 1.2%, p = 0.92). ST was adjudicated by the Academic 
Research Consortium (ARC) as not being restricted to the 
angiographically determined events. Treatment of diabetic 
patients with PES compared with BMS was associated with 
a signiﬁ  cant and durable reduction in TLR over the 4-year 
follow-up period (12.4% vs 24.7%, p   0.0001). The relative 
safety and efﬁ  cacy of PES compared with BMS in diabetic 
patients extended to both those requiring and not requiring 
insulin. The rates of both efﬁ  cacy and safety end-points may 
vary in a less selected patient population in which stents 
are implanted in more complex and higher-risk situations. 
Frequent scenarios in DM patients are: true bifurcation 
lesions, multivessel disease, and acute MI. Interestingly, 
Kuchulakanti and colleagues144 assessed the correlates and 
outcomes of angiographically proven ST with DES (PES and 
SES) in a population of 2974 consecutive patients. Compared 
with patients without ST, patients with ST had a higher fre-
quency of diabetes, acute post-procedural renal failure, and 
chronic renal failure. There were more bifurcation lesions, 
type C lesions, and a trend for smaller-diameter stents. 
Discontinuation of clopidogrel was more frequent in these 
patients (36.8% vs 10.7%; p = 0.0001). The author stressed 
that careful management is warranted in patients with 
renal failure and in those undergoing treatment for in-stent Vascular Health and Risk Management 2009:5 115
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restenosis and bifurcations. These data reﬂ  ect outcomes from 
a real world population. Speciﬁ  c and sufﬁ  ciently powered, 
well-deﬁ  ned, randomized studies are needed to understand 
the real safety of DES in DM.
Clinical and therapeutic implications
The concern of late ST has emerged with the widespread use 
of DES, during the last 5 years. To date long-term safety has 
not been addressed in a powered, randomized trial, speciﬁ  -
cally designed for diabetic patients. These aforementioned 
studies, and meta-analysis results, seem to minimize the 
problem, showing similar rates of late ST, but these data 
must be interpreted with caution for many reasons. The 
heterogeneity and end-point deﬁ  nitions differed among 
the pooled trials; diabetic patients were often a subgroup in 
the study population because these trials were not designed 
to study diabetics exclusively. Because original data were 
not accessed, no information on patient glycemic control was 
available, and discrepancies arising from variability in the 
deﬁ  nition of diabetes, and ST, could not be resolved.
Available data so far show that diabetes is an independent 
predictor of ST; despite the use of dual antiplatelet therapy, 
patients with DM have a higher risk of developing adverse 
clinical outcomes. Recent observations suggest that this risk 
may relate to platelet dysfunction typical of DM, leading to 
inadequate platelet inhibition.
Research results in general imply a complex and multi-
disciplinary treatment for this type of patient. When PCI is 
indicated for a diabetic patient, DES is the device of choice. 
At the same time, tight glycemic control and compliance with 
guidelines for antiplatelet drug management are mandatory. 
A speciﬁ  c antiplatelet regimen in DM may be useful. Novel 
antiplatelet agents with a strong action against the hyper-
activated “diabetic platelet” may be needed.
Conclusions
Coronary revascularization in diabetic patients remains a 
challenge. The introduction of DES has improved PCI out-
comes, but the problem of atherothrombotic complications, 
including ST, persist for which DM is recognized as an inde-
pendent predictor. Inadequate responsiveness to currently 
available antiplatelet agents, including ASA and clopidogrel, 
may contribute to these poor outcomes. Novel antiplatelet 
agents under advanced clinical investigation may provide 
future treatment alternatives to tackle the “diabetic platelet”. 
Indeed, dedicated studies on selected diabetic patients are 
warranted, to understand the real magnitude and signiﬁ  cance 
of the problem, and ﬁ  nd an appropriate solution.
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